arca biopharma inc (ABIO:NASDAQ CM)
Burton E. Sobel M.D.
Former Director and Chairman of the Compensation Committee, Ariad Pharmaceuticals Inc.
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 7 different industries.|
Dr. Burton E. Sobel M.D. was a Professor of the Department of Medicine for the University of Vermont College of Medicine since 1994 and also as a Professor of Biochemistry. Dr. Sobel served as Medical & Clinical Advisor of Synvista Therapeutics, Inc. Dr. Sobel had been the Editor of Circulation and Editor of Coronary Artery Disease since 1989. Dr. Sobel served as President-elect for the Society for Experimental Biology and Medicine. His research interest concerned was ...
Corporate Headquarters*8001 Arista Place
Broomfield, Colorado 80021
Board Members Memberships*
Former Director and Chairman of the Compensation Committee
Former Director, Member of Nominating & Corporate Governance Committee and Member of Audit Committee
Former Independent Director, Chairman of Nominating & Governance Committee and Member of Compensation Committee
Former Director, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee
Former Director, Chairman of Nominating & Governance Committee and Member of Audit Committee
Brigham and Women's Hospital
Harvard Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Ron Squarer BSc (Biochemistry), MBA||Chief Executive Officer and Director|
Array BioPharma, Inc.
|Daniel R. Passeri MSc., J.D.||Chief Executive Officer and Director|
|Michael M. Morrissey Ph.D.||Chief Executive Officer, President and Director|
|Paul A. Friedman M.D.||Chief Executive Officer, President, Director, Member of Non-Management Stock Option Committee and Member of Finance Committee|
|Adelene Q. Perkins||Chairman of The Board, Chief Executive Officer and President|
Infinity Pharmaceuticals, Inc.
|$536.0K||Compensation as of Fiscal Year 2012.|